current

These companies make good things happen through meaningful transformation of ideas from conception to commercialization. They have the passion and commitment it takes to turn entrepreneurial vision into market reality. As a result, people have better lives. We like that. We’re proud of every company and grateful for the opportunity to be part of their story.

current portfolio

  • Aurinia Pharmaceuticals is a clinical stage pharmaceuticalcompany focused on the global nephrology market. Its lead drug, voclosporin, isa novel calcineurin inhibitor being developed for the treatment of LupusNephritis.

  • BAROnova is developing a novel, non-surgical device for thetreatment of obesity. It consists of a TransPyloric Shuttle device that isinserted into the stomach through the mouth using a simple, 10-minuteendoscopic procedure.

  • Cardiac Dimensions is developing a minimally invasiveimplantable product to treat mitral valve regurgitation associated with congestive heart failure.

  • Carrot Insights is a global social enterprise aim to build innovative national reward platforms which can support behaviour shifts on a mass scale.

  • Celtaxsys is a clinical-stage drug discovery and development company developing novel immuno-modulators as treatments for serious inflammatory diseases, including cystic fibrosis and severe acne.

  • Corvia is a private medical device company based in Massachusetts developing a catheter-delivered implant for treating diastolic heart failure.

  • Endotronix, Inc., a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. 

  • Engene has a novel proprietary method to deliver therapeutic proteins to the gastrointestinal (GI) tract to treat diseases of the GI tract as well as diseases that may be attenuated via the actions of therapeutic proteins at the GI tract.

  • Exact Imaging is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer.

  • First Aid Shot Therapy® (F.A.S.T.) is a consumer healthcare company focused on over-the-counter medicine in liquid shot form.

  • Formation Biologics engineers novel, tumour selective Antibody-Drug Conjugates (ADC's) for the treatment of Cancer.   These ADC's prevent collateral damage to normal tissues and results in safe and significantly more effective anti-cancer treatments compared to prior generation chemotherapeutics and biological treatments.

  • G1 Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of novel small-molecule therapies to address significant unmet needs in oncology.

  • Gladius is a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections.

  • Opsens' unique Fractional Flow Reserve (FFR) guidewire brings together a robust sensing technology and an advanced material construction, delivery a tool that is accurate, reliable, and easy-to-use; saving time and cost and improve the success rates in challenging peripheral and coronary interventions.

  • Based in Montreal, OsteoQC is developing new drug candidates for the treatment of bone-related diseases.

  • Pharmasset was acquired by Giliad in 2011 for $11 Billion for their oral therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

  • Spinal Kinetics has developed and commercialized a unique technology designed to replicate the natural vertebral disc in its structure and physiologic range of motion in all planes, including axial compression.

  • Swift Medical is a leader in imaging technology and data analytics solutions for the healthcare industry. Swift Wound, together with Swift’s Metrics dashboard, represents a new generation in wound care management technology.

  • Think Research developed cloud-based tools that empower clinicians to deliver the best evidence-based care to patients and drive better patient outcomes.

  • Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.

  • Ception Therapeutics was acquired by Cephalon Inc. in March 2010 in a deal worth $350 million plus significant future millstones. Cephalon was subsequently acquired by Teva in 2011.

  • Corus Pharmaceuticals, developer of Aztreonam for treatment of cystic fibrosis and Lidocaine for treatment of oral corticosteroid dependent asthma was acquired by Gilead in August 2006 for $365 million.

  • Imagia believes that the technology of deep learning is a key to the future of medical image processing, with its ability to merge large and diverse data sources to make more accurate predictions.

  • KAI Pharmaceuticals, developer of novel therapeutics for kidney disease was acquired by Amgen in 2012 for US$315 million.

  • Lumira was an early investor in MAKO Surgical prior to its IPO. MAKO markets both its RIO Robotic-Arm Interactive Orthopedic system and proprietary implants for minimally invasive orthopedic knee procedures.

  • Morphotek, developer of therapeutic antibodies for the treatment of cancer, inflammatory and infectious diseases was acquired by Eisai in April 2007 for $325 million.

  • Alexza Pharmaceuticals is focused on the development and manufacture of novel proprietary products using its proprietary Staccato®system which vaporizes an excipient-free drug to form an orally inhaled aerosol.

  • Alveolus, developer of next generation non-vascular interventional stent technology for use in the lungs was acquired by Merit Medical Systems Inc. in February 2008.

  • In November 2010 Archemix agreed to sell all of its hemophilia-related assets to Baxter International Inc. in deal worth up to $305 million. 

  • Cardiovascular Systems is a medical device company that develops and commercializes interventional technologies for the treatment of cardiovascular disease.

  • Lumira Capital led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005.

  • Guava Technologies was acquired for $22.6 million by Millipore Inc. in February, 2009. 

  • From the time we invested in 2002 to our exit in 2006 ISTA launched three products in the United States to treat diseases of the eye.

  • NephroGenex is a biotechnology company developing advancedtreatments for kidney disease.

  • Lumira Capital exited public company Renovis, developer of therapeutics for Neurological and inflammatory disease fields in 2005 and 2006.

  • Resonant Medical, developer of 3D ultrasound image-guided radiotherapy products was acquired by Elekta in May of 2010 for $30 million in cash.

  • Automated Breast Ultrasound company U-Systems was acquired by GE healthcare in late 2012.

  • Vendorlink.ca is a provider of web-based vendor management solutions for Canadian hospitals.  The Company's assets were acquired  by Intellicentics in late 2014.